Pharmaceutical - Pharmaceutical, Pricing

Filter

Current filters:

PharmaceuticalPricing

Popular Filters

1 to 25 of 607 results

PhRMA comments on Medicare Rights Center paper

25-07-2014

“Finding viable solutions to contain Medicare costs is critically important, but imposing price controls…

FinancialHealthcarePharmaceuticalPricingUSA

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

21-07-2014

International medical humanitarian organization Médecins Sans Frontières has said that high prices…

Anti-viralsAntiretroviral drugHIVHIV/AIDSMSFPharmaceuticalPricing

Attractions and challenges of Poland’s pharmaceutical market

Attractions and challenges of Poland’s pharmaceutical market

17-07-2014

Not only is Poland the largest pharmaceutical market in the Central & Eastern Europe region and the sixth…

HealthcareMarkets & MarketingPharmaceuticalPolandPricing

The EMA’s scientific advice to pharma companies is a conflict of interest, says industry coalition

The EMA’s scientific advice to pharma companies is a conflict of interest, says industry coalition

15-07-2014

A coalition of major European medicines advocates has criticized the European Medicines Agency for providing…

EuropeEuropean Medicines AgencyHealth technology assessment bodiesPharmaceuticalPricingRegulation

Multinational and Indian drugmakers to face another price cap

Multinational and Indian drugmakers to face another price cap

15-07-2014

In a major blow to drug companies, India's National Pharmaceutical Pricing Authority (NPPA) has decided…

IndiaNational Pharmaceutical Pricing AuthorityPharmaceuticalPricing

UK cancer patients face increasing coverage restriction, US report shows

UK cancer patients face increasing coverage restriction, US report shows

11-07-2014

New US research released yesterday quantifies the extent to which centralized value assessments by the…

OncologyPharmaceuticalPricingRegulationUK

Orphan drug approvals rise, but high costs pose challenges for patients

Orphan drug approvals rise, but high costs pose challenges for patients

10-07-2014

Although the pace of approvals for new orphan drugs - medicines that treat relatively rare conditions…

EuropePharmaceuticalPricingRare diseasesRegulationUSA

UK’s NICE backs Lundbeck drug for alcohol dependence

UK’s NICE backs Lundbeck drug for alcohol dependence

10-07-2014

In new draft guidance, the UK drug watchdog the National Institute for Health and Care Excellence (NICE)…

LundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Report: Why pharmaceutical prices drop once drugs are off-patent

Report: Why pharmaceutical prices drop once drugs are off-patent

07-07-2014

The USA-based Pacific Research Institute has released a new report, titled The Economics of Pharmaceutical…

GlobalPatentsPharmaceuticalPricing

Further Indian drug price cuts, and price control categorization likely

30-06-2014

In order to make drugs more affordable to the country’s public, the Indian government is likely to…

FinancialIndiaPharmaceuticalPoliticsPricing

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

27-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Price cuts mean Australia’s PBS is sustainable, trade group argues

Price cuts mean Australia’s PBS is sustainable, trade group argues

20-06-2014

Yet more price cuts announced yesterday to come into effect on October 1 for 300 medicines reaffirms…

AustraliaHealthcarePharmaceuticalPricing

UK’s NICE recommends Sucampo’s Amitiza for CIC

UK’s NICE recommends Sucampo’s Amitiza for CIC

18-06-2014

The UK health care watchdog the National Institute of Health and Care Excellence (NICE) has released…

AmitizaGastro-intestinalsPharmaceuticalPricingRegulationSucampoUK

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

17-06-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGermanyInvokanaJanssen-CilagJohnson & JohnsonPharmaceuticalPricingRegulation

New drug prices in India to be capped by NPPA

New drug prices in India to be capped by NPPA

16-06-2014

In order to keep a lid on the escalating cost of drugs, India's drug price regulator has decided to fix…

IndiaMachineryNatco PharmaPharmaceuticalPharmacyPoliticsPricingRetail priceSun Pharmaceuticals

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

13-06-2014

People in England with advanced skin cancer should be able to receive ipilimumab as a first treatment…

Bristol-Myers SquibbOncologyPharmaceuticalPricingRegulationUKYervoy

Large increase seen in insulin use, out-of-pocket costs for type 2 diabetes

11-06-2014

Largely attributable to the widespread adoption of insulin analogs, use of insulin among patients with…

DiabetesHealthcarePharmaceuticalPricingUSA

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

PhRMA chief defends US prescription drug costs and value

PhRMA chief defends US prescription drug costs and value

30-05-2014

The head of the US trade group Pharmaceutical Research and Manufacturers of America has issued a strong…

HealthcarePharmaceuticalPricingUSA

1 to 25 of 607 results

Back to top